ERBB2 and breast cancer: Although rapid onset (11–13 weeks) of multifocal mammary tumors was observed in the majority of activated neu transgenic mice, this mutation has never been observed in human cancers, which only present amplification of the HER2 gene copy number and consequent overexpression of HER2 protein on the cell membrane.